Use UniProt Q13370 as the stable identity anchor, then attach disease evidence before program review.
CHEMBL290 Target Snapshot
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B · SINGLE PROTEIN · Homo sapiens
Research home keeps recent targets
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Switch target
Move to another high-traffic target or paste a specific ChEMBL target ID.
Frame the target before identity details
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Protein identity stays anchored to UniProt Q13370. Use UniProt Q13370 as the stable identity anchor, then attach disease evidence before program review.
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B
Review this target as cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B, mapped to UniProt Q13370. Sequence length is 1112 aa.
Protein source · UniProt accession via ChEMBL component mappingCross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B as ChEMBL target CHEMBL290, mapped to UniProt Q13370. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Start with the right source
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B is the right protein anchor across sources, using UniProt Q13370 as the stable mapping.
Jump to Protein ContextUse this block first when you need the strongest disease program and evidence level in one place.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardBasic Information
Verify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q13370 |
Next Actions
UniProt Target Context
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B |
| UniProt Accession | Q13370 |
| Component Type | Protein |
| Sequence Length | 1112 aa |
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B
How to read this target
Review this target as cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B, mapped to UniProt Q13370. Sequence length is 1112 aa.
Clinical Phase Distribution
Activity Type Distribution
Top Inhibitors (by pChEMBL)
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL338860 | 10.31 | IC50 | 0.049 | Preclinical |
| CHEMBL339210 | 10.17 | IC50 | 0.068 | Preclinical |
| CHEMBL131355 | 9.96 | IC50 | 0.11 | Preclinical |
| CHEMBL129668 | 9.89 | IC50 | 0.13 | Preclinical |
| CHEMBL131111 | 9.89 | IC50 | 0.13 | Preclinical |
| CHEMBL128456 | 9.72 | IC50 | 0.19 | Preclinical |
| CHEMBL338179 | 9.62 | IC50 | 0.24 | Preclinical |
| CHEMBL128391 | 9.59 | IC50 | 0.26 | Preclinical |
| CHEMBL128621 | 9.52 | IC50 | 0.3 | Preclinical |
| CHEMBL129283 | 9.48 | IC50 | 0.33 | Preclinical |
pChEMBL Value Distribution
Approved Drugs
Assay Landscape
Binding — 82 assays, 523 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 56 | 162 | 5.8 |
| cell-based format | 24 | 42 | 6.6 |
| assay format | 2 | 319 | 7.2 |
ADME — 2 assays, 0 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 1 | 0 | — |
| single protein format | 1 | 0 | — |
Functional — 1 assays, 1 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 1 | 1 | 7.3 |